We are IntechOpen, the world’s leading publisher of Open Access books Built by scientists, for scientists
Selection of our books indexed in the Book Citation Index in Web of ScienceTM Core Collection (BKCI)
http://dx.doi.org/10.5772/intechopen.68759
Vreeman RC et al. Journal of the International AIDS Society 2017, 20(Suppl 3):21497 http://www.jiasociety.org/index.php/jias/article/view/21497 | http://dx.doi.org/10.7448/IAS.20.4.21497
Recommendations for a Public Health approach and considerations for policy-makers and managers
Journal of Social Aspects of HIV/AIDS VOL. 13 NO. 1 2016
To link to this article: https://doi.org/10.1080/17290376.2016.1226942
Research Article
PLOS ONE | https://doi.org/10.1371/journal.pone.0192791 February 15, 2018
Recommendations for a public health approach
HIV/AIDS Programme
Best Practices Guidelines
Accessed: 06.11.2019
Technical Brief
Damon Barrett, Gonçalo Figueiredo Augusto, Martiani Oktavia, Jeanette Olsson, Mira Schneiders and Kate Welch provided background papers and literature reviews which informed this technical series.
Eurosurveillance
Impact Factor 5.7
June 2015
www.eurosurveillance.org
Featuring a series of articles on HIV and STI epidemiology, prevention and control among MSM in Europe
Consolidated Guidelines
Geneva, 2016
The End TB Strategy
UNAIDS Series: Engaging uniformed services in the fight against AIDS - Case Study 1
Fighting AIDS
UNAIDS/10.03E / JC1767E (English original, March 2010) ISBN 978 92 9 173849 6
WHO recommends that pre-exposure prophylaxis (PrEP) be offered as an additional prevention choice for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
HIV drug resistance has been rarely reported among PrEP users who tested
...
HIV positive in randomized controlled trials or open-label studies. However, PrEP-selected HIV drug resistance could potentially negatively impact the effectiveness of treatment options among PrEP users who acquire HIV, since there is a potential for overlapping resistance profiles between antiretroviral drugs used for both PrEP and first-line antiretroviral therapy.
more
PQDx 0053-006-00 WHO
PQ Public Report
June/2016, version 2.0